Disponible en / Available in: Español
With the support of the University of Valencia, Evolving Therapeutics was created by Respiralia to combat infections caused by multidrug-resistant bacteria.
The fight against multi-resistant bacteria
It is predicted that in the year 2050 humanity will face the biggest pandemic ever seen. It will be caused by infections by multi-resistant bacteria or super bacteria, which are capable of evolving to defend themselves against antibiotics.
Currently, bacteria such as Mycobacterium abscessus, MRSA or Burkholderia cepacia are very difficult to eradicate once they colonize a person’s body, since they have become resistant to known antibiotics.
Phage therapy as a solution to the problem
Evolving Therapeutics, S. L., a spin-off based at the science park of the University of Valencia, aims to develop the phage therapy research project and produce specific phages for different bacteria that affect humans, animals and plants.
In the medium term, the clinical trial on Mycobacterium abscessus infection in Cystic Fibrosis will open the doors to the incorporation of this treatment in the public health portfolio.
The Evolving Therapeutics, S. L. team.
Dr. Pilar Domingo Calap, specialized in phage therapy in human and animal health, and Dr. María Luisa Domingo Calap, specialized in phage therapy in plant health, lead this project.
Their long experience in this field will allow them to lead a young research team dedicated body and soul to fight against the threat of these super bacteria.
Awards for an innovative project
The company Evolving Therapeutics is born with two awards under its arm. The first is the Hackathon Agrotec Startup 2022, a call created for entrepreneurship proposals based on innovative ideas in agri-food. The second is the Valencia Start Up 2022, a call for the promotion of R+D+I companies in the process of creation.
A bet with great social impact
The Respiralia Foundation is committed to this research project for several reasons. One of them, of great importance because of its alignment with our objectives, is to offer a compassionate use treatment at zero cost for people with Cystic Fibrosis, mainly, at least during the first 5 years or until this treatment enters the public health portfolio.